Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
68.560,40
0,07%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Millendo Therapeutics Inc (MLND) Millendo Therapeutics Inc (MLND) Notizie

MLND

Millendo Therapeutics (MLND)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MLND
DataOraFonteTitoloSimboloCompagnia
20/06/202322:54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MLNDMillendo Therapeutics Inc
16/06/202322:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MLNDMillendo Therapeutics Inc
10/05/202322:25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:MLNDMillendo Therapeutics Inc
01/05/202322:16Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:MLNDMillendo Therapeutics Inc
01/05/202322:12Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:MLNDMillendo Therapeutics Inc
14/02/202320:57Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:MLNDMillendo Therapeutics Inc
14/02/202318:11Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:MLNDMillendo Therapeutics Inc
04/10/202214:01Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:MLNDMillendo Therapeutics Inc
21/06/202214:06Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MLNDMillendo Therapeutics Inc
31/05/202213:35Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MLNDMillendo Therapeutics Inc
27/05/202215:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:MLNDMillendo Therapeutics Inc
17/05/202200:13Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:MLNDMillendo Therapeutics Inc
11/05/202221:43Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:MLNDMillendo Therapeutics Inc
02/05/202222:07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:MLNDMillendo Therapeutics Inc
22/04/202222:01Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:MLNDMillendo Therapeutics Inc
01/04/202212:24Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:MLNDMillendo Therapeutics Inc
29/03/202222:59Edgar (US Regulatory)Annual Report (10-k)NASDAQ:MLNDMillendo Therapeutics Inc
30/09/202116:47Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:MLNDMillendo Therapeutics Inc
23/07/202122:39Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:MLNDMillendo Therapeutics Inc
22/06/202122:00GlobeNewswire Inc.Tempest and Millendo Announce Stockholder Approval of MergerNASDAQ:MLNDMillendo Therapeutics Inc
11/06/202123:20Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:MLNDMillendo Therapeutics Inc
10/05/202123:13Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:MLNDMillendo Therapeutics Inc
13/04/202119:50Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:MLNDMillendo Therapeutics Inc
13/04/202116:07Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:MLNDMillendo Therapeutics Inc
30/03/202113:26TipRanksMillendo To Merge With Tempest Therapeutics; Shares TankNASDAQ:MLNDMillendo Therapeutics Inc
29/03/202113:00Business WireTempest and Millendo Announce Proposed Merger AgreementNASDAQ:MLNDMillendo Therapeutics Inc
05/01/202115:00Business WireMillendo Therapeutics Provides Pipeline and Business UpdateNASDAQ:MLNDMillendo Therapeutics Inc
09/11/202014:30Business WireMillendo Therapeutics Reports Third Quarter 2020 Operating and Financial ResultsNASDAQ:MLNDMillendo Therapeutics Inc
24/09/202014:30Business WireMillendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R AntagonistNASDAQ:MLNDMillendo Therapeutics Inc
03/09/202014:30Business WireMillendo Therapeutics to Participate in September Investor ConferencesNASDAQ:MLNDMillendo Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MLND

La tua Cronologia

BOV
HBSA3M
Hidrovias DO Brasil ON
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network